Candel Therapeutics (CADL) Accumulated Depreciation (2020 - 2025)

Candel Therapeutics' Accumulated Depreciation history runs 6 years deep, the most recent figure standing at $3.6 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 15.67% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (up 15.67% YoY), while the FY2025 annual figure was $3.6 million, up 15.67% from the prior year.
• Accumulated Depreciation came in at $3.6 million for Q4 2025 at Candel Therapeutics, up from $3.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $3.6 million in Q2 2025 to a low of $167000.0 in Q2 2021.
• A 5-year average of $1.9 million and a median of $1.8 million in 2023 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation surged 383.51% in 2022 and gained 15.67% in 2025, its largest moves.
• Candel Therapeutics' Accumulated Depreciation stood at $352000.0 in 2021, then soared by 220.74% to $1.1 million in 2022, then surged by 85.03% to $2.1 million in 2023, then jumped by 47.25% to $3.1 million in 2024, then gained by 15.67% to $3.6 million in 2025.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $3.6 million, $3.4 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison